TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: It has been further reported that p53 activation by SIRT1 inhibition, in combination with imatinib increased the killing of CML progenitor cells [36] and that the combination of nutlin3a with imatinib enhanced CML apoptosis [37].